COMPARE/Markin vs Grok with MCP
vsvs Grok with MCP: cheap tokens, unproven decisions
+17–35% ARPU against holdoutObserved range across Markin deployments, measured on treated cohorts.
Grok with MCP is a fast, low-cost way to reason over live data, and cheap tokens make wider use realistic. Markin operates a layer above: versioned growth skills that size hypotheses in money, prove them against randomised holdouts, and use trained models rather than language models for the per-customer work.
The short answerLast updated: August 2026
Grok's argument is price and immediacy, and it is a good one. But cheaper tokens do not turn a recommendation into a proven result. The gap is not how much reasoning costs; it is that nothing in a chat loop sizes the idea, checks it can reach significance, or holds out a control group.
01
Grok with MCP
xAI's assistant with MCP tool access, positioned on speed, cost and real-time signal from the open web and X.
Choose it when you need fast, cheap reasoning and live external context alongside your own data.
- Low cost per token
- Real-time signal
- Fast responses
02
Markin
An autonomous growth-science team generating, sizing, launching and reading hypotheses against your customer base continuously.
Choose it when the number has to hold up in a board pack, not just sound right in a thread.
- Sized in euros
- Holdout on every action
- Executes in your stack
Line by line
The same ten questions, answered for both.
| Dimension | Markin | Grok with MCP |
|---|---|---|
| What it is | An autonomous growth-science team: it investigates why revenue per customer is stuck and acts on what it finds. | A general assistant with tool access, tuned for speed and price, with live external signal. |
| What it decides | Which commercial opportunity deserves to exist for each customer this week, what it is worth, and when the right answer is to do nothing. | What to answer. Commercial decisions remain with the reader. |
| Where hypotheses come from | Generated by Markin from customer, product, pricing and technical-health data, then sized before anyone builds anything. | Generated quickly and cheaply, which means more of them and no filter on which deserve attention. |
| How a hypothesis is evaluated | Sized in money on the eligible population, filtered by statistical power, then killed or kept by a randomised holdout. | None. Volume of suggestions goes up; the share that is testable does not. |
| Scope of action | Marketing, product, pricing and technical-health hypotheses, arbitrated against each other in one queue. | Analysis and commentary over connected tools and public signal. |
| Which models do the work | A routed mix: frontier language models to write and explain, small cheap models for volume classification, and classical ML and deep learning, uplift, survival, time series, embeddings, for the numbers. | One model for everything, chosen for price rather than for the task. |
| What the cost scales with | Decisions taken and revenue proven, not tokens burned. Per-customer reasoning is handled by the cheap layers by design. | Lower per token, which helps, but still priced by questions asked rather than by decisions taken. |
| How the work reaches the customer | Written back into the systems you already run, as attributes, events or API calls. Markin does not add a new customer-facing surface. | Manual: a human moves the idea into the system that can act. |
| How impact is proven | A randomised holdout on every decision. The reported number is incremental revenue and ARPU, not attributed conversions. | Not part of the product. |
| Where the data sits | Reads context where it already lives, warehouse, CDP, product and billing systems. No new system of record. | Live tool reads plus public sources. |
| Governance and control | Every action carries its hypothesis, its expected value, its guardrails and its control group, reviewable before launch. | Tool permissions and workspace policy. |
| Time to a verified number | One revenue theme, one channel, one holdout: a defensible incremental number inside 90 days. | Seconds to an opinion, unchanged to a verified result. |
| Best fit | Large B2C bases where the constraint is how many good hypotheses get tested, not how many messages get sent. | Teams that want cheap, fast reasoning and live external context. |
What is at stake
A decision layer is not a tool line item. It moves ARPU on the whole base, every month.
Installed base
2.0M
customers at $24 ARPU / month
Addressable revenue
$259.2M
per year, reachable base
Verified ARPU uplift
+17% to +35% ARPU
on treated cohorts, against holdout
What that is worth
$44.1M – $90.7M
incremental revenue per year
Measured on treated cohorts against a randomised holdout, read over a full measurement window rather than the first weeks. Anonymised range across Markin deployments in large B2C bases; your own holdout is the number that decides. The figures above apply that range to the reachable share of the base on this page's assumptions; they are arithmetic, not a forecast for your business.
Run it on your own numbersThe unsolved part
Cheaper answers, same missing half
Lowering the price of a suggestion increases how many suggestions you get. It does nothing about the part that costs real money: choosing between them, testing them properly and retiring the ones that stop working.
- More candidates, no sizing, so the queue gets longer rather than better.
- No power check, so undetectable effects still get built and argued about.
- No holdout, so the reported win is attribution wearing a new interface.
- No memory of what already failed, so the same idea returns next quarter.
Hypothesis space
Everything a human growth scientist would look at.
Most growth problems are not message problems. Markin is not restricted to the campaign surface: if something is holding ARPU back, it is in scope, and it gets tested the same way.
Marketing
The classic surface, but chosen per customer rather than per segment, and always against a holdout.
- Which offer this specific customer is worth making
- Channel and timing chosen per person, not per campaign
- Contact pressure and fatigue arbitrated across every programme
- Win-back economics: who is worth a discount and who is not
Product
Where the customer actually experiences the value, and where most silent revenue loss happens.
- Onboarding steps that lose customers before first value
- A feature with high retention correlation that half the base never discovers
- Paywall and upgrade prompt placement
- In-product surfaces used as a treatment arm, not just email and push
Commercial
Pricing, packaging and the shape of the offer itself, tested rather than argued about.
- Plan and bundle structure by cohort
- Discount depth against margin, not against conversion alone
- Annual versus monthly framing per customer
- Dunning and involuntary churn recovery sequences
Technical health
Anomalies nobody asked it to look for. This is the category no decisioning engine covers.
- A checkout error rate that rose on one device and one region
- Payment failures concentrated in a single issuer or method
- A broken deeplink quietly killing a high-value journey
- Latency or delivery degradation eating conversion before any message does
Think of Markin as a data science and growth team that never sleeps: it investigates, forms hypotheses, ships them into your own stack and proves each one against a control group, at a volume no human team can reach.
Job to be done
The same work, at a different throughput.
Nothing below needs a tool that does not exist. It needs the work to happen continuously instead of once a quarter, and to be proven against a holdout instead of argued about.
| Job to be done | With grok with mcp alone | With Markin |
|---|---|---|
| Notice that revenue per customer is drifting in a segment | Someone spots it in a dashboard review, weeks after it started. | Detected as a signal the day the drift clears noise, with the segment already sized. |
| Explain why it is happening | An analyst is pulled off the roadmap for a two-week investigation. | An investigation runs automatically and returns the drivers with their evidence. |
| Come up with hypotheses worth testing | A workshop produces the handful of ideas the room happened to think of. | Hypotheses are written continuously across marketing, product, pricing and technical health. |
| Decide which hypotheses deserve budget | Prioritised by seniority and gut feel, with no size attached. | Each one is sized in revenue and ranked before anything is built. |
| Choose the next best action for one customer | Segment rules and campaign calendars decide, refreshed when someone has time. | Chosen per customer, per moment, against everything else competing for that customer. |
| Actually launch it | A ticket to the lifecycle team, then a slot in next month's calendar. | Executed inside the systems you already run, with no new channel to adopt. |
| Prove it caused the revenue | Reported against non-qualifiers or a global holdout, if at all. | Every decision carries a randomised control group; uplift is read against it. |
| Kill what does not work | Programmes survive because nobody owns retiring them. | Failing to beat control retires the programme automatically. |
| Do all of it again next week | Capacity-bound: four to eight tests a quarter. | Hundreds of hypotheses in flight in parallel, continuously. |
Honest take
What Grok with MCP does better.
A comparison that only flatters one side is not worth reading. These are the cases where we would tell you to stay where you are.
Price genuinely matters, and Grok is aggressive on it
Cost per token is one of the few things that decides whether an AI workflow can run at volume at all. That is the same reasoning that drives our own model routing, so it would be inconsistent to dismiss it.
Real-time external signal is something we do not have
Markin reads your systems. It does not watch the open web or social platforms for the story breaking around your brand right now, and for some teams that context is genuinely valuable.
Fast and cheap changes who gets to ask
When a question costs almost nothing, more people ask more questions, and that has real value independent of any platform.
Where Markin fits
Not a replacement. A growth-science team on top.
Markin applies the same cost logic Grok is built on, but at the level of decisions: the cheapest model class that can do a step correctly does that step, and expensive reasoning is spent only where it changes the outcome.
Cost per decision, not per question
Volume work runs on small and trained models.
Skills with evaluations
Sizing, design, reading and arbitration are versioned components.
Proof, not opinion
Randomised holdouts on every action.
Evidence standard
Most of this category reports its own lift.
None of the major engagement, CDP or personalisation vendors publishes an independently verified uplift figure for its decisioning product. Where numbers exist, they come from vendor-commissioned studies or single-customer case studies with no disclosed holdout methodology. The most rigorous public research in the category is not flattering to anyone, including us, which is exactly why we build against it.
BCG reports that when organisations adopt rigorous incrementality testing, they typically find 20% to 40% of their active next-best-action programmes deliver marginal to negative lift.
Independent researchBCG, How Measurement Is Evolving in Next-Best Action (2026)The same research flags novelty effects, new programmes show inflated early results, and recommends 8 to 12 weeks before drawing conclusions.
Independent researchBCG, How Measurement Is Evolving in Next-Best Action (2026)Global-holdout, programme-level ROI measurements often overstate impact through halo effects, pull-forward effects and experiment contamination.
Independent researchBCG, How Measurement Is Evolving in Next-Best Action (2026)
How Markin holds itself to it
- Every decision Markin makes carries a control group. Uplift is reported against that holdout, not against the customers who did not qualify.
- Results are read over a full measurement window rather than in the first weeks, so novelty is not mistaken for effect.
- Programmes that fail to beat control are retired automatically. Killing decisions that do not pay is part of the loop, not an annual review.
- The one figure we quote about ourselves is a range, not an average: +17% to +35% ARPU on treated cohorts against a randomised holdout, across Markin deployments in large B2C bases. We publish no industry benchmark, because we could not source one we would be willing to defend. Your holdout is the number that matters.
Time to value
90 days to a number that survived a holdout.
No replatform, no data migration, no rebuild of the channels you already run. If the first cohorts do not beat control, nothing scales and you have lost a quarter, not a roadmap.
Weeks 0–2
Read the context you already have
Markin connects to the data and the channels you run today, grok with mcp included. No migration, no replatform, no new source of truth.
Weeks 3–6
First sized opportunities in test
Opportunities are ranked by expected value, treatments are chosen per customer, and the first cohorts go live with a randomised holdout attached.
Weeks 7–12
First verified incremental revenue
Results are read over a full measurement window. What beats control scales; what does not is retired. Nothing scales on a number that has not survived a holdout.
Which one you should pick.
Choose Markin if
- The output must be a decision per customer with a control group attached.
- Ideas need to be ranked in money before they consume anyone's week.
- Marketing, product, pricing and technical-health hypotheses compete in one queue.
- Results are reported to finance and have to survive scrutiny.
- The base is large enough that untested ideas are expensive.
Choose Grok with MCP if
- You want cheap, fast reasoning available to everyone.
- Live external and social signal matters to your work.
- The job is commentary and exploration, not execution.
- You are not running controlled experiments on the base.
When you don’t need Markin.
- You want the cheapest possible way to ask questions of your data.
- The base is too small for controlled measurement.
- Nothing may be actioned without individual human approval.
Questions buyers ask.
If tokens keep getting cheaper, does Markin still make sense?
More than before. Cheap reasoning makes candidate generation nearly free, which makes selection the bottleneck. Sizing in money, power checks and holdouts are what turn a large pile of suggestions into a small set of proven wins.
What does Grok do better?
Cost and speed per answer, and live external signal from the open web. Markin reads your systems and does not watch the outside world in real time.
Does Markin use cheap models too?
Constantly. Most per-customer work runs on small models and on trained ML, propensity, uplift, survival and time series. Frontier models are reserved for writing hypotheses, explaining findings and drafting briefs.
Can we use both?
Yes, and that is the common pattern: an assistant for questions, Markin for decisions and proof.
How is Markin different from the decisioning or AI already inside grok with mcp?
A decisioning engine ranks actions a human already defined, inside the campaign surface it was given. Markin forms the hypotheses itself, marketing, product, pricing or a technical anomaly holding growth back, sizes them, executes them inside grok with mcp and your product surfaces, and reads each one against a randomised holdout. It behaves like a data science and growth team, not like an optimiser.
Does Markin only test messages and offers?
No. Anything a human growth scientist would investigate is in scope: onboarding friction, feature adoption, pricing and packaging, dunning, and technical health issues such as a checkout error rate or a broken deeplink quietly killing conversion. Marketing is one of four hypothesis domains, not the boundary.
What is the business case for adding Markin on top of grok with mcp?
On a large B2C base, a small move in ARPU is a large number in absolute terms, because it applies to the whole installed base every month rather than to a campaign. Across Markin deployments the verified range on treated cohorts is +17% to +35% ARPU against a randomised holdout. The point is not more messages: it is finding the highest-value action per customer, launching it, and proving it against control before it scales.
How long before it pays for itself?
First sized opportunities are in test within six weeks and the first holdout-verified result lands inside 90 days. Payback depends on your base, margin and programme cost, the calculator on this page computes it from your own numbers, after applying the 20% to 40% haircut BCG finds when next-best-action programmes are incrementality-tested.